Back to search
FDAFDA · Food and drugs·Recall number D-0855-2017

SATO CLEAR (naphazoline hydrochloride) Redness Reliever Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-044-01

Published May 31, 2017 · Recall initiated: February 16, 2017

Summary

FDA records drug Class II recall D-0855-2017, published May 31, 2017 and initiated February 16, 2017. Recalling firm: Sato Pharmaceutical Inc.; Status: Terminated; Reported quantity: 4,790 bottles; Lot: Lot #: WXWZ, Exp. March 2019; WXTS, Exp. October 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sato Pharmaceutical Inc.
Distributor
US: Hawaii, Guam, Saipan, SPI
Lot
Lot #: WXWZ, Exp. March 2019; WXTS, Exp. October 2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SATO CLEAR (naphazoline hydrochloride) Redness Reliever Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-044-01 recalled?

Yes. FDA published recall D-0855-2017 on May 31, 2017. Reported hazard: Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

What should I do if I have this product?

Voluntary: Firm initiated · Letter